| Literature DB >> 28494238 |
Daniela Boehm1, Mark Jeng1, Gregory Camus1, Andrea Gramatica2, Roland Schwarzer2, Jeffrey R Johnson3, Philip A Hull1, Mauricio Montano2, Naoki Sakane4, Sara Pagans1, Robert Godin5, Steven G Deeks6, Nevan J Krogan3, Warner C Greene2, Melanie Ott7.
Abstract
Transcriptional latency of HIV is a last barrier to viral eradication. Chromatin-remodeling complexes and post-translational histone modifications likely play key roles in HIV-1 reactivation, but the underlying mechanisms are incompletely understood. We performed an RNAi-based screen of human lysine methyltransferases and identified the SET and MYND domain-containing protein 2 (SMYD2) as an enzyme that regulates HIV-1 latency. Knockdown of SMYD2 or its pharmacological inhibition reactivated latent HIV-1 in T cell lines and in primary CD4+ T cells. SMYD2 associated with latent HIV-1 promoter chromatin, which was enriched in monomethylated lysine 20 at histone H4 (H4K20me1), a mark lost in cells lacking SMYD2. Further, we find that lethal 3 malignant brain tumor 1 (L3MBTL1), a reader protein with chromatin-compacting properties that recognizes H4K20me1, was recruited to the latent HIV-1 promoter in a SMYD2-dependent manner. We propose that a SMYD2-H4K20me1-L3MBTL1 axis contributes to HIV-1 latency and can be targeted with small-molecule SMYD2 inhibitors.Entities:
Keywords: H4K20me1; HIV; L3MBTL1; LTR; SMYD2; latency
Mesh:
Substances:
Year: 2017 PMID: 28494238 PMCID: PMC5490666 DOI: 10.1016/j.chom.2017.04.011
Source DB: PubMed Journal: Cell Host Microbe ISSN: 1931-3128 Impact factor: 21.023